133 related articles for article (PubMed ID: 2149284)
1. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study.
Hietanen T; Baltina D; Johansson R; Numminen S; Hakala T; Helle L; Valavaara R
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S37-40. PubMed ID: 2149284
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.
Pyrhönen S; Valavaara R; Heikkinen M; Rissanen P; Blanco G; Nordman E; Holsti LR; Hajba A
J Steroid Biochem; 1990 Jun; 36(3):227-8. PubMed ID: 2142239
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.
Bishop J; Murray R; Webster L; Pitt P; Stokes K; Fennessy A; Olver I; Leber G
Cancer Chemother Pharmacol; 1992; 30(3):174-8. PubMed ID: 1385761
[TBL] [Abstract][Full Text] [Related]
4. Phase II trials with toremifene in advanced breast cancer: a review.
Valavaara R
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S31-5. PubMed ID: 2149283
[TBL] [Abstract][Full Text] [Related]
5. [The results of a comparative clinical study of the antiestrogenic preparations toremifene and tamoxifen in locally advanced and disseminated breast cancer].
Konstantinova MM; Gershanovich MA
Vopr Onkol; 1990; 36(10):1182-6. PubMed ID: 2147527
[TBL] [Abstract][Full Text] [Related]
6. Phase III studies of toremifene in metastatic breast cancer.
Pyrhönen SO
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S41-6. PubMed ID: 2149285
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical study of high-dose toremifene in patients with advanced breast cancer.
Modig H; Borgström S; Nilsson I; Westman G
J Steroid Biochem; 1990 Jun; 36(3):237-8. PubMed ID: 2142243
[TBL] [Abstract][Full Text] [Related]
8. Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication.
Modig H; Borgström S; Nilsson I; Westman G
J Steroid Biochem; 1990 Jun; 36(3):235-6. PubMed ID: 2142242
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of toremifene in breast cancer patients. A phase II study.
Valavaara R; Pyrhönen S; Heikkinen M; Rissanen P; Blanco G; Nordman E; Taskinen P; Holsti LR; Hajba A
J Steroid Biochem; 1990 Jun; 36(3):229-31. PubMed ID: 2142240
[TBL] [Abstract][Full Text] [Related]
10. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study.
Gundersen S
J Steroid Biochem; 1990 Jun; 36(3):233-4. PubMed ID: 2142241
[TBL] [Abstract][Full Text] [Related]
11. Phase II experience with toremifene in the treatment of ER-positive breast cancer of postmenopausal women.
Valavaara R
Cancer Invest; 1990; 8(2):275-6. PubMed ID: 2144787
[No Abstract] [Full Text] [Related]
12. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene.
Valavaara R; Tuominen J; Johansson R
Cancer; 1990 Dec; 66(11):2264-9. PubMed ID: 2147123
[TBL] [Abstract][Full Text] [Related]
13. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study.
Valavaara R; Pyrhönen S; Heikkinen M; Rissanen P; Blanco G; Thölix E; Nordman E; Taskinen P; Holsti L; Hajba A
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):785-90. PubMed ID: 2968265
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment.
Jönsson PE; Malmberg M; Bergljung L; Ingvar C; Ericsson M; Ryden S; Nilsson I; Terje IJ
Anticancer Res; 1991; 11(2):873-5. PubMed ID: 1829600
[TBL] [Abstract][Full Text] [Related]
15. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
Horvath G; Stendahl U; Kalling M; Fernö M; Himmelmann A; Hajba A
Anticancer Res; 1990; 10(2A):323-5. PubMed ID: 2140668
[TBL] [Abstract][Full Text] [Related]
16. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group.
Gershanovich M; Garin A; Baltina D; Kurvet A; Kangas L; Ellmén J
Breast Cancer Res Treat; 1997 Sep; 45(3):251-62. PubMed ID: 9386869
[TBL] [Abstract][Full Text] [Related]
17. Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication.
Ebbs SR; Roberts J; Baum M
J Steroid Biochem; 1990 Jun; 36(3):239. PubMed ID: 2142244
[TBL] [Abstract][Full Text] [Related]
18. Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer.
Hietanen T; Hakala T; Baltina D; Johansson R; Numminen S; Helle L; Valavaara R; Thölix E
Oncology (Williston Park); 1997 May; 11(5 Suppl 4):37-40. PubMed ID: 9165505
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.
Kohler PC; Hamm JT; Wiebe VJ; DeGregorio MW; Shemano I; Tormey DC
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S19-26. PubMed ID: 2149280
[TBL] [Abstract][Full Text] [Related]
20. Introduction to toremifene.
Kangas L
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S3-7. PubMed ID: 2149282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
